The preclinical evaluation of lung cancer therapy is a vital stage in the drug development process, designed to systematically assess the safety, efficacy, and feasibility of candidate drugs through comprehensive experiments and studies. This critical phase provides the scientific foundation to advance promising therapies into clinical trials.
In vitro studies are mainly conducted under laboratory conditions, using cell or tissue models, and are characterized by high throughput, low cost, and high controllability.
Lung cancer diseases and their therapy development have certain market characteristics, which is why Alfa Cytology focuses on the preclinical development of lung cancer therapies.
In vivo studies can better reflect the tumor microenvironment, immune response, and pharmacokinetics by simulating the growth and progression of lung cancer in live animals.
Alfa Cytology offers extensive preclinical assessment services and cutting-edge assays to meet lung cancer and immunology-related project needs. As a leading provider of specialized testing services for preclinical lung cancer, we focus on developing endpoint tests that provide accurate and reliable data to provide quantifiable metrics, evaluate therapy effects across multiple parameters, and derive safe and precise insights to guide critical decisions for your project.
Pharmacodynamics Evaluation
Pharmacokinetics evaluation
Toxicology Evaluation
For the preclinical evaluation of lung cancer therapies, Alfa Cytology provides the lung cancer animal model technology platform and the Bioinformation technology platform, the two core supporting platforms. They support the research from two aspects of experimental model construction and data analysis respectively.
The lung cancer animal model technology platform focuses on the development and utilization of animal models to simulate the biological characteristics of human lung cancer for drug screening, efficacy evaluation, and mechanism research.
The Bioinformation technology platform leverages computational biology, data analytics, and artificial intelligence to deeply mine and integrate experimental data to provide data-driven insights for lung cancer research.
Frontier Science
Customized Services
Extensive Experience
Quality Assurance
What types of data and reports do you provide?
Alfa Cytology provides detailed laboratory reports, raw data, pharmacodynamic and pharmacokinetic data, toxicological evaluation reports, biomarker data, and multi-omics analysis reports.
Do you have successful preclinical evaluations of novel therapies for lung cancer?
Yes, we have many successful cases in the development of novel therapies for lung cancer, including immunotherapy, targeted therapy, and cell therapy.
Do your preclinical services support the development of immunotherapies, cell therapies, and targeted therapies?
Yes, we have extensive experience in the development of immunotherapies (such as immune checkpoint inhibitors and CAR-T cell therapy), cell therapies, and targeted therapies (such as small molecule inhibitors and antibody-drug conjugations).
For research use only.
